报告人：魏明辉，Scientist，Division of Cancer Epidemiology & Genetics, National Cancer Institute, NIH, USA
时间：2008.6.10 上午10：00――11：00
地点：闵行实验B楼307室
内容简介：
结合报告人近几年的研究成果，向听众介绍癌症尤其是肾癌发生、发展的遗传学以及分子生物学机理，了解与肾癌有关的基因及其药靶确证的研究新进展。
Kidney cancer is not a single disease, it is made up of a number of different types of tumor occurred in the kidney, each with distinctive genetic changes, morphology and prognoses. Kidney cancer occurs in both sporadic (non-inherited) and hereditary (inherited) forms. There are four well-defined hereditary syndromes associated with the renal cancer: von Hippel Lindau (VHL), hereditary papillary renal carcinoma (HPRC), Birt Hogg Dubé (BHD), and hereditary leiomyomatosis and renal cell carcinoma (HLRCC). Based on the concept that sporadic and inherited forms of cancer are caused by mutations of the same genes, cancer geneticists studied the families with multiple members affected with renal cancer and identified the genes that predisposed to the inherited kidney cancers: 1) the VHL gene is associated with clear cell renal carcinoma; 2) the c-Met oncogene responsible for HPRC is associated with type I papillary renal carcinoma; 3) the BHD gene is associated with chromophobe and oncocytoma and clear cell renal carcinoma and 4) the fumarate hydratase (FH) gene responsible for HLRCC is associated with type II papillary renal carcinoma. Identification of a renal cancer gene opens the door to the development of DNA diagnostic tests for the disease, and recent advances in understanding the molecular pathway of kidney cancer genes provides the basis for the development of targeted therapeutics.